Precision dermatology powered by microbial and genetic engineering

Developing novel therapeutics to treat adverse skin conditions and disease


Azitra is a clinical-stage precision dermatology company that leverages its extensive knowledge of genetic engineering, proteomics, and the skin microbiome to create and develop novel products for the treatment of skin diseases.

Learn More


Azitra is leveraging microbial and protein engineering to solve the challenges of skin diseases through three strategies:

Learn More

Product pipeline

Azitra’s product pipeline includes two live biotherapeutic product candidates and one protein candidate for precision dermatology. The Company anticipates beginning a first-in-human trial of its engineered microbe, ATR-12, for Netherton syndrome in 2023. The current pipeline consists of:

ATR-12: LEKTI-secreting auxotrophic S. epidermidis for Netherton syndrome
ATR-04: Auxotrophic S. epidermidis for EGFR inhibitor-associated rash
ATR-01: Filaggrin protein for ichthyosis vulgaris

handle shape